Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for PAHC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -1.615M
March 31, 2026 -2.30M
December 31, 2025 -18.98M
September 30, 2025 16.34M
June 30, 2025 -7.766M
March 31, 2025 -32.22M
December 31, 2024 276.32M
September 30, 2024 -29.20M
June 30, 2024 1.787M
March 31, 2024 4.854M
December 31, 2023 -14.70M
September 30, 2023 1.296M
June 30, 2023 -6.332M
March 31, 2023 0.284M
December 31, 2022 3.716M
September 30, 2022 29.32M
June 30, 2022 12.39M
March 31, 2022 10.26M
December 31, 2021 -14.58M
September 30, 2021 8.265M
June 30, 2021 4.637M
March 31, 2021 -11.55M
December 31, 2020 -16.54M
September 30, 2020 6.458M
June 30, 2020 14.98M
Date Value
March 31, 2020 -10.98M
December 31, 2019 -27.00M
September 30, 2019 63.93M
June 30, 2019 -7.999M
March 31, 2019 -2.982M
December 31, 2018 -4.86M
September 30, 2018 11.73M
June 30, 2018 -0.711M
March 31, 2018 -9.52M
December 31, 2017 -19.39M
September 30, 2017 17.84M
June 30, 2017 -1.975M
March 31, 2017 -20.72M
December 31, 2016 -19.38M
September 30, 2016 -11.67M
June 30, 2016 -17.62M
March 31, 2016 59.22M
December 31, 2015 -4.764M
September 30, 2015 13.55M
June 30, 2015 -0.917M
March 31, 2015 -5.197M
December 31, 2014 -4.48M
September 30, 2014 -4.757M
June 30, 2014 23.32M
March 31, 2014 -15.36M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Zoetis, Inc. -813.00M
Merck & Co., Inc. 1.762B
ANI Pharmaceuticals, Inc. -4.647M
Corcept Therapeutics, Inc. -2.037M
Veru, Inc. -0.0519M